Impact of the COVID-19 pandemic
| Question | Answering options | N (%) |
| Have you been tested for COVID-19? | Yes | 1809 (14) |
| No | 10 949 (86) | |
| Do not know | 31 (0) | |
| Missing/no reply | 0 (–) | |
| If yes, was the test positive?* | Yes | 40 (2) |
| No | 1668 (92) | |
| Do not know | 94 (5) | |
| Missing | 7 (–) | |
| Characteristics of patients with positive COVID-19 test, n=40 | Characteristics | N (%) |
| Gender, female, n (%) | 20 (50) | |
| Age, years, median (IQR) | 54 (47–67) | |
| HAQ, median (IQR) | 0.38 (0.09–0.88) | |
| Diagnosis | ||
| RA | 23 (58) | |
| PsA | <5 patients | |
| AxSpA | 9 (23) | |
| Other | <5 patients | |
| bDMARD treatment, yes | 15 (38) | |
| Comorbidities, yes | 20 (50) | |
| Smoking | ||
| Current | <5 | |
| Previous | 13 | |
| Never | 24 |
Testing for SARS-CoV-2 by June 2020. N=12 789.
*If positive, what was the consequence (>1 answer allowed): self-isolation at home (n=33), hospitalisation (7), other (2), do not know (3).
AxSpA, axial spondyloarthritis; bDMARD, biological disease modifying antirheumatic agent; HAQ, health assessment questionnaire; PsA, psoriatic arthritis; RA, rheumatoid arthritis.